Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

Overview of attention for article published in Cost Effectiveness and Resource Allocation, August 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

blogs: 1 blog

twitter: 3 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 73 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,716 followers.

RT @BresMedOfficial: Congratulations to Chrissy Almond and Indeg Sly, two members of our Health Economics Analysis team, who are co-authors…

09 Aug 2018

Reply Repost Favourite

Congratulations to Chrissy Almond and Indeg Sly, two members of our Health Economics Analysis team, who are co-authors on a new publication: "Cost‑effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden" https://t.co/LSMpxeSYK5

08 Aug 2018

Reply Repost Favourite

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden https://t.co/Ky1Tg2nJ8u https://t.co/cN7bYaZr0h

03 Aug 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.